Budget impact analysis of sarilumab for the treatment of rheumatoid arthritis in patients with an inadequate response to conventional synthetic DMARD or TNF inhibitor therapies [Corrigendum]
Ferrufino CP, Munakata J, Wei W, et al. Clinicoecon Outcomes Res. 2018;10: 805—819. On page 810, Table 4, Drug costs column, Methotrexate, the Unit WAC was listed as $1 however it should have been $2.36. On page 817, Table S2, the monitoring costs for (A) csDMARD-IR and (B) TNF-IR...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Book |
| Published: |
Dove Medical Press,
2019-01-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Ferrufino CP, Munakata J, Wei W, et al. Clinicoecon Outcomes Res. 2018;10: 805—819. On page 810, Table 4, Drug costs column, Methotrexate, the Unit WAC was listed as $1 however it should have been $2.36. On page 817, Table S2, the monitoring costs for (A) csDMARD-IR and (B) TNF-IR were changed. Read the original article |
|---|---|
| Item Description: | 1178-6981 |